Late-Life Depression: More Than a Mood Disorder
neuroscienceCME WebcastPremiere Date: Tuesday, May 6, 2014
This activity offers CE credit for:
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, May 6, 2015
Note: Credit Is No Longer Available
|J. Craig Nelson, MD
Leon J. Epstein Professor of Geriatric Psychiatry
Director of Geriatric Psychiatry
University of California, San Francisco
San Francisco, CA
|David C. Steffens, MD, MHS
Professor and Chair
Department of Psychiatry
University of Connecticut Health Center
Major depressive disorder (MDD) is the most prevalent mental health condition and late-life depression is associated with significant morbidity and mortality and a tendency towards chronicity.(1) Depression in a geriatric population presents a unique set of challenges to the treating clinician. MDD adversely affects the brain and can be manifested as disturbed cognitive function, disrupted sleep, appetite disturbance, and behavioral abnormalities in addition to the alteration of mood.(2)
This enduring replay of the symposium recorded at the 2014 AAGP Annual Meeting integrates patient vignettes to demonstrate the unique challenges and nuances that may complicate the diagnosis and treatment of late-life depression. The voice of the patient will offer an impactful, clinical perspective to the educational activity.
- Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guidelines for the treatment of patients with major depressive disorder, third edition. PsychiatryOnline Website. http://psycho.silverchair.com/content.aspx?aID=654003. Published October 2010. Accessed February 9, 2014.
- Roose SP, Sackheim HA (eds). Late-Life Depression. Oxford University Press: New York, NY: 2004: pp. xxii.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants.
The Make One Change Statement for this activity is: As recommended by the American Psychiatric Association practice guidelines for major depression, elderly patients should be screened annually for depression.
At the end of this CE activity, participants should be able to:
- Implement an individualized treatment plan that proactively evaluates the efficacy of current treatment regimens and considers the role of emerging treatments on the effectiveness of clinical management and achieving remission in late-life depression.
- Implement treatment strategies that address residual symptoms of depression and cognition and provide follow-up care for patients with major depressive disorder, which includes: three visits in the 90 days following the diagnosis and assessment of response to treatment.
Provided by the American Association for Geriatric Psychiatry. Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.
Geriatric psychiatrists and psychiatrists
CME Credit (Physicians):
The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Association for Geriatric Psychiatry (AAGP) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships with Commercial Interests
American Association for Geriatric Psychiatry (AAGP) and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of AAGP and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
AAGP and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Nelson has disclosed that he has received research support from the National Institute of Mental Health (NIMH) and Health Resource and Services Administration (HRSA). He has received lecture honoraria from (Otsuka Asia) Otsuka Pharmaceutical Co., Ltd. He serves as a consultant to Bristol-Myers Squibb Company; Eli Lilly and Company; Lundbeck; Otsuka America, Inc.; Pfizer Inc.; Shire; and Sunovion Pharmaceuticals Inc. He has disclosed stock ownership in Atossa Genetics, Inc.
Dr. Steffens has no disclosures to report.
Disclosures were obtained from the AAGP staff: Nothing to Disclose.
Robert Kennedy (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
AAGP, CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).